Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Total 13F shares
-
31,506,425
-
Share change
-
+1,011,133
-
Total reported value
-
$1,008,520,000
-
Put/Call ratio
-
269%
-
Price per share
-
$32.01
-
Number of holders
-
49
-
Value change
-
+$31,200,638
-
Number of buys
-
27
-
Number of sells
-
27
Institutional Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q4 2020
As of 31 Dec 2020,
ADC Therapeutics SA - Common Shares (ADCT) was held by
49 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,506,425 shares.
The largest 10 holders included
FMR LLC, Redmile Group, LLC, JPMORGAN CHASE & CO, PRICE T ROWE ASSOCIATES INC /MD/, ALLIANCEBERNSTEIN L.P., Vantage Consulting Group Inc, Grosvenor Holdings, L.L.C., BAKER BROS. ADVISORS LP, EVENTIDE ASSET MANAGEMENT, LLC, and Polar Capital Holdings Plc.
This page lists
49
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.